Neuronetics Q4 Earnings Call Highlights
View original at finance.yahoo.comNeuronetics Q4 Earnings Call Highlights Neuronetics logo Key Points Board appointed Dan Reuvers as CEO effective March 23, as Neuronetics transitions leadership while continuing its strategy to operate a vertically integrated mental-health company combining NeuroStar technology and Greenbrook clinics…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
In the first full year post-acquisition, Neuronetics grew revenue, improved cash generation, and strengthened its platform for supporting both its NeuroStar device business and Greenbrook's clinic-based care delivery network
60% confidenceCompass has about seven strategic collaborations for commercial readiness and Greenbrook is one of them
60% confidenceFull-year 2026 operating cash flow is expected to be negative $13 million to negative $17 million, with the highest cash burn in the first quarter and improvement beginning in the second quarter, with positive operating cash flow in the second half
60% confidenceCompass has about seven strategic collaborations for commercial readiness and Greenbrook is one of them
60% confidenceCOMP360 would be administered in supervised doses within a clinic setting, without a daily or recurring protocol, and would be administered under a REMS protocol similar to Spravato
60% confidenceNeuroStar revenue (systems plus treatment sessions) was $18.3 million, representing 9% growth year-over-year on a pro forma basis
60% confidenceCompass has completed two phase 3 studies showing highly statistically significant and clinically meaningful results, including durable improvement through at least 26 weeks after one or two doses
60% confidenceThe Spravato rollout is nearly complete, with 84 clinics providing the treatment
60% confidenceOn an adjusted pro forma basis, revenue increased 23% versus the prior year
60% confidenceThe fourth-quarter gross margin was the company's highest quarterly margin of the year, citing clinic efficiency efforts and favorable product mix
60% confidenceOperating cash burn improved sequentially each quarter during 2025, from negative $17 million in the first quarter to positive $0.9 million in the fourth quarter
60% confidenceCompass Pathways has completed two phase 3 studies showing highly statistically significant and clinically meaningful results, including durable improvement through at least 26 weeks after one or two doses
60% confidenceCash provided by operations in the fourth quarter was positive $0.9 million
60% confidenceTotal treatment volume across Spravato and TMS rose 18% year-over-year in the fourth quarter
60% confidenceDan Reuvers is a medical-device leader with experience scaling commercial healthcare businesses
60% confidenceThe Spravato rollout is nearly complete with 84 clinics providing the treatment
60% confidenceThe $5 million principal payment to Perceptive did not come from restricted cash and the debt paydown would reduce annual interest expense by close to $600,000
60% confidenceFull-year 2026 operating cash flow is expected to be negative $13 million to negative $17 million, with the highest cash burn in the first quarter and improvement beginning in the second quarter, with positive operating cash flow in the second half
60% confidenceThe company's strategy following the Greenbrook acquisition was to build a vertically integrated mental health company combining technology, clinical infrastructure, and scale to expand patient access to treatment
60% confidenceClinic revenue was $23.5 million, representing 37% adjusted pro forma growth, driven by increased treatments across both NeuroStar TMS and Spravato
60% confidenceFourth-quarter total revenue was $41.8 million, up 86% year-over-year, primarily due to the inclusion of Greenbrook operations
60% confidenceTotal treatment volume across Spravato and TMS rose 18% year-over-year in the fourth quarter
60% confidenceThe Greenbrook network is positioned to offer REMS-compliant therapies and expects only limited incremental investment to support COMP360 if approved, given alignment with existing Spravato operations
60% confidenceClinic revenue was $23.5 million, representing 37% adjusted pro forma growth, driven by increased treatments across both NeuroStar TMS and Spravato
60% confidenceNeuroStar revenue (systems plus treatment sessions) was $18.3 million, representing 9% growth year-over-year on a pro forma basis
60% confidenceOn an adjusted pro forma basis, revenue increased 23% versus the prior year
60% confidenceThe company shipped 49 systems in the quarter, with average selling price above its target for a fourth consecutive quarter
60% confidenceCash provided by operations in the fourth quarter was positive $0.9 million. Operating cash burn improved sequentially each quarter during 2025, from negative $17 million in the first quarter to positive $0.9 million in the fourth quarter
60% confidenceCOMP360 would be administered in supervised doses within a clinic setting, without a daily or recurring protocol, and would be administered under a REMS protocol similar to Spravato
60% confidenceThe field team held more than 400 educational meetings, resulting in more than 210 new referral sites by year-end
60% confidence